All rights reserved.”
“Background: Little information is available for the outcomes of conversion to total shoulder arthroplasty (TSA) of failed hemiarthroplasty (HA) FDA approved Drug Library datasheet implanted for fractures or fracture-dislocations of the proximal humerus.\n\nMaterials and methods: We evaluated the clinical and radiographic results

in 16 patients who underwent conversion of HA to TSA due to pain and shoulder disfunction. Patients were a mean age of 63 years at revision, which was occurred a mean of 3.3 years after the HA. The main prerequisites for conversion were forward flexion to at least 60 degrees, no massive cuff tear, or severe resorption or nonunion of the tuberosities. In all cases, a modular prothesis was used in the HA, uncemented in 14 and cemented in 2. The latest follow-up was a mean of 4.6 years after revision.\n\nResults: The mean

Constant score was 50.6 (range, 33-69), with an average increase of 11.9 points compared with the preoperative score (P = .001). In 75% of patients, the mean score was 54.6 (average increase, 15.1 points). The lowest scores occurred in patients with a cemented prosthesis that needed to be removed, and in 1 patient who had loosening of the implanted glenoid that was revised.\n\nConclusions: Conversion A-1331852 mouse of HA to TSA can improve the preoperative condition in most patients aged in their 50s or 60s in the absence of rotator cuff deficiency and severe bone loss of the proximal humerus.\n\nLevel of evidence: Level IV, Case Series, Treatment Study. (C) 2012 Journal of Shoulder and Elbow Surgery Board of Trustees.”
“Introduction. Cancer and venous thromboembolism are frequently associated.\n\nState of the art. – Venous thromboembolism

is associated with a worse prognosis in patients CT99021 with cancer. Thrombosis in cancer patients is related to the expression of tissue factor and other procoagulants by tumour cells. Surgery, chemotherapy and antiangiogenic agents are also associated with an increased risk of thrombosis. Venous thromboembolism may be the first manifestation of cancer, the risk being especially increased during the first six months following an unexplained episode of idiopathic thrombosis. Current evidence does not suggest that a systematic screening for cancer after an unexplained thrombosis is associated with a clinical benefit. Risk factors for thrombosis specific to the cancer population have been identified. A recent controlled trial suggests that low-molecular weight heparin may reduce the incidence of venous thromboembolism in patients with cancer. These results need to be confirmed. Treatment of venous thromboembolism in cancer patients is primarily based on low-molecular weight heparin administered for three or six months.\n\nPerspectives. – Low-molecular weight heparin may increase the survival of patients with cancer through a direct effect on tumour biology. Several clinical trials are underway to confirm this hypothesis.\n\nConclusion.